CTNM · Categories · Form 4

CTNM - SEC Form 4 insider transactions

Contineum Therapeutics Inc. (CTNM) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for CTNM

• 17h
  SEC Form 4 filed by Director Miralles Gines Diego

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 17h
  SEC Form 4 filed by Director Lyons-Williams Lori

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 17h
  SEC Form 4 filed by Director Ware Olivia C

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 17h
  SEC Form 4 filed by Director Schimmelpennink Evert B.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 17h
  SEC Form 4 filed by Director Ignelzi Troy A.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 17h
  SEC Form 4 filed by Director Brady Todd R.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 17h
  SEC Form 4 filed by Director Boyce Sarah

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 25d
  Chief Scientific Officer Lorrain Daniel S. sold $54,862 worth of shares (4,170 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 139,372 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 56d
  Chief Scientific Officer Lorrain Daniel S. sold $54,694 worth of shares (4,170 units at $13.12) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 143,542 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 81d
  SEC Form 4 filed by Lorrain Daniel S.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 116d
  Chief Scientific Officer Lorrain Daniel S. sold $62,585 worth of shares (4,170 units at $15.01), decreasing direct ownership by 3% to 151,882 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 116d
  CMO & Head of Development Watkins Tim exercised 3,611 shares at a strike of $4.50 and sold $54,220 worth of shares (3,611 units at $15.02) (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 120d
  CEO and President Stengone Carmine N. exercised 7,100 shares at a strike of $1.26 and sold $113,728 worth of shares (7,100 units at $16.02) (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 120d
  Chief Scientific Officer Lorrain Daniel S. exercised 8,124 shares at a strike of $1.01 and sold $130,164 worth of shares (8,124 units at $16.02) (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 126d
  Chief Scientific Officer Lorrain Daniel S. exercised 100 shares at a strike of $1.01 and sold $1,600 worth of shares (100 units at $16.00) (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 133d
  CEO and President Stengone Carmine N. sold $6,400 worth of shares (400 units at $16.00) and exercised 400 shares at a strike of $1.26 (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 133d
  Chief Scientific Officer Lorrain Daniel S. exercised 400 shares at a strike of $1.01 and sold $6,400 worth of shares (400 units at $16.00) (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 141d
  Chief Scientific Officer Lorrain Daniel S. sold $62,305 worth of shares (4,170 units at $14.94), decreasing direct ownership by 3% to 156,052 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 147d
  SEC Form 4 filed by General Counsel and Corp Sec Healy John Stephen

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 147d
  SEC Form 4 filed by Chief Financial Officer Slover Peter T

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 147d
  SEC Form 4 filed by CEO and President Stengone Carmine N.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 147d
  SEC Form 4 filed by Chief Scientific Officer Lorrain Daniel S.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 147d
  CMO & Head of Development Watkins Tim exercised 3,611 shares at a strike of $4.50 and sold $51,188 worth of shares (3,611 units at $14.18) (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 171d
  Chief Scientific Officer Lorrain Daniel S. sold $43,543 worth of shares (4,170 units at $10.44), decreasing direct ownership by 3% to 160,222 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 178d
  CMO & Head of Development Watkins Tim exercised 3,611 shares at a strike of $4.50 and sold $43,558 worth of shares (3,611 units at $12.06) (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 178d
  Chief Scientific Officer Lorrain Daniel S. sold $51,009 worth of shares (4,170 units at $12.23), decreasing direct ownership by 2% to 164,392 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 365d
  SEC Form 4 filed by Director Boyce Sarah

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 365d
  SEC Form 4 filed by Director Schimmelpennink Evert B.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 365d
  SEC Form 4 filed by Director Brady Todd R.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 365d
  SEC Form 4 filed by Director Ignelzi Troy A.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 365d
  SEC Form 4 filed by Director Lyons-Williams Lori

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 365d
  SEC Form 4 filed by Director Ware Olivia C

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 365d
  SEC Form 4 filed by Director Miralles Gines Diego

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 424d
  SEC Form 4 filed by CMO & Head of Development Watkins Tim

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 466d
  SEC Form 4 filed by Director Miralles Gines Diego

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 511d
  SEC Form 4 filed by General Counsel and Corp Sec Healy John Stephen

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 511d
  SEC Form 4 filed by Chief Financial Officer Slover Peter T

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 511d
  SEC Form 4 filed by Chief Scientific Officer Lorrain Daniel S.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 511d
  SEC Form 4 filed by CMO & Sr VP, Clinical Dev. Huhn Stephen L.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 511d
  SEC Form 4 filed by CEO and President Stengone Carmine N.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 576d
  Chief Scientific Officer Lorrain Daniel S. sold $16,177 worth of shares (1,010 units at $16.02), decreasing direct ownership by 0.60% to 168,562 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 583d
  Chief Scientific Officer Lorrain Daniel S. sold $101,421 worth of shares (6,190 units at $16.38), decreasing direct ownership by 4% to 169,572 units (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 681d
  CMO & Sr VP, Clinical Dev. Huhn Stephen L. exercised 12,800 shares at a strike of $1.01 (SEC Form 4)

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 732d
  SEC Form 4 filed by Director Boyce Sarah

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 753d
  SEC Form 4 filed by Healy John Stephen

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Stengone Carmine N.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Slover Peter T

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Lorrain Daniel S.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Huhn Stephen L.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Ignelzi Troy A.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Ware Olivia C

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Lyons-Williams Lori

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Brady Todd R.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 758d
  SEC Form 4 filed by Schimmelpennink Evert B.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
• 767d
  SEC Form 4 filed by Ignelzi Troy A.

  4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

Other CTNM categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends